About: A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 March 2010

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2010 (ast) наукова стаття, опублікована в березні 2010 (uk) scientific article published on 11 March 2010 (en) مقالة علمية نشرت في 11 مارس 2010 (ar) 2010 թվականի մարտի 11-ին հրատարակված գիտական հոդված (hy)
publication date	wds:Q37709472-086D7032-2BAF-437F-8307-2CCBACA1B9C2
publication date	2010-03-11 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37709472-9EE066E6-C07A-42EB-A793-35F68726933A
language of work or name	English
cites work	wds:Q37709472-45985D00-9BA0-42C0-A636-140B4EB54078
cites work	Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
author name string	wds:Q37709472-14B545A2-DD06-45B3-BE2B-2CDA6B7F8009 wds:Q37709472-161E8DF8-1D32-4650-82F6-2E5A0F4F815F wds:Q37709472-3C50277C-BDE0-4A6E-A4E8-BB9F45FB7B63 wds:Q37709472-5517D5A1-91EC-47D1-9BB5-27B34417805E wds:Q37709472-7CDA6844-F533-4910-960B-900EA0568F5A wds:Q37709472-A8FDC735-3604-4D76-B770-E73DB81BC7BC wds:Q37709472-B980F325-85AE-4ABB-99A6-2FD4BAECC309 wds:Q37709472-DB72032D-D8D3-490B-8110-AA3D94694781
author name string	Michael Richards Michael Williams Peter Collins Ri Liesner Elizabeth Chalmers John Hanley Vicky Vidler Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation
rdfs:label	A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (en) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (nl) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (ast)
skos:prefLabel	A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (en) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (nl) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (ast)
name	A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (en) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (nl) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (ast)
title	wds:Q37709472-C7831A2E-35F1-4B82-AE9E-0427C4199837
title	A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. (en)
page(s)	wds:Q37709472-75876B9D-1406-4827-A0E2-94775D290E65
page(s)	498-507
instance of	wds:Q37709472-24556C11-4703-410B-B22C-D2B45D8D66FD wds:Q37709472-cc0e5656-e92c-4bae-8034-1644c4c06057
instance of	review article scholarly article
main subject	wds:Q37709472-CCEBF52D-4FA1-4D2E-A70E-EB9074EB877F wds:Q37709472-CF647B15-FD3E-4646-8577-A05009878D55 wds:Q37709472-D18A0883-9C27-4EE8-96E2-C26AC013A250 wds:Q37709472-F8172081-8B38-4EB5-93F0-59B1A525AFC1
main subject	United Kingdom hemophilia A Coagulation factor VIII hemophilia
PubMed ID	wds:Q37709472-EF916DDD-5E65-40CC-99C0-BCCC7873E911
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20230411
PubMed ID	20230411
published in	wds:Q37709472-8B5E7112-88EC-4C26-9193-1482BD85BBBF
published in	British Journal of Haematology
issue	wds:Q37709472-08952122-A0BE-4373-BBDF-D389E16E787C
volume	wds:Q37709472-EAE6E09B-E611-4FF6-B1E7-55021C6F1831
issue	4
volume	149
DOI	wds:Q37709472-A93A83D8-86FE-4776-BF46-D421A65B2262
DOI	http://dx.doi.org/10.1111/J.1365-2141.2010.08139.X
DOI	10.1111/J.1365-2141.2010.08139.X
ResearchGate publication ID	wds:Q37709472-1C1B4725-187C-4690-8423-999DAC7161F4
ResearchGate publication ID	41968063
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37709472
is cites work of	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand The burden of bleeding in haemophilia: is one bleed too many? Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A. Prophylaxis in real life scenarios Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis Aspects of prophylactic treatment of hemophilia Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades Simoctocog alfa for the treatment of hemophilia A. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties Personalized prophylaxis Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline [HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy] Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software